Jill Adler-Moore

Summary

Affiliation: California State Polytechnic University
Country: USA

Publications

  1. ncbi request reprint Effect of tissue penetration on AmBisome efficacy
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Curr Opin Investig Drugs 4:179-85. 2003
  2. pmc Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 49:4895-902. 2005
  3. pmc Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, 91768, USA
    Antimicrob Agents Chemother 50:2122-31. 2006
  4. ncbi request reprint Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B
    Peter J Smith
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 59:941-51. 2007
  5. pmc Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 52:259-68. 2008
  6. ncbi request reprint AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Avenue, Pomona, CA 91768, USA
    J Antimicrob Chemother 49:21-30. 2002
  7. doi request reprint Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine
    Jill Adler-Moore
    California State Polytechnic University Pomona, 3801 West Temple Ave, Pomona, CA 91768, USA
    Vaccine 29:4460-8. 2011
  8. doi request reprint Amphotericin B lipid preparations: what are the differences?
    J P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Clin Microbiol Infect 14:25-36. 2008
  9. pmc Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections
    J A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, California, USA
    Antimicrob Agents Chemother 56:218-30. 2012
  10. ncbi request reprint Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis
    Jill P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 54:1096-102. 2004

Collaborators

  • Gerard M Jensen
  • Jon A Olson
  • Richard T Proffitt
  • Julie Schwartz
  • J A Olson
  • Peter J Smith
  • William A Ernst
  • D Hahka
  • R T Proffitt
  • A George
  • J Schwartz
  • M Cecilia Dignani
  • David Constable
  • Hyung J Kim
  • Gary Fujii
  • Wendy Tai
  • Terrence M Tumpey
  • Airan D A Jansen
  • Donald V Cramer
  • P J Smith

Detail Information

Publications11

  1. ncbi request reprint Effect of tissue penetration on AmBisome efficacy
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Curr Opin Investig Drugs 4:179-85. 2003
    ....
  2. pmc Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 49:4895-902. 2005
    ..In conclusion, the combination of liposomal amphotericin B with an echinocandin markedly improved the therapeutic outcome in murine C. glabrata systemic infection...
  3. pmc Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, 91768, USA
    Antimicrob Agents Chemother 50:2122-31. 2006
    ..In conclusion, although both drugs were effective in prolonging survival at 12 mg/kg, the reduced nephrotoxicity of L-AMB increased its therapeutic index, allowing for its safe and effective use at 15 or 20 mg/kg...
  4. ncbi request reprint Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B
    Peter J Smith
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 59:941-51. 2007
    ....
  5. pmc Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 52:259-68. 2008
    ..In conclusion, the efficacy and toxicity of these two liposomal amphotericin B products were significantly different, and thus, the products were not comparable...
  6. ncbi request reprint AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Avenue, Pomona, CA 91768, USA
    J Antimicrob Chemother 49:21-30. 2002
    ....
  7. doi request reprint Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine
    Jill Adler-Moore
    California State Polytechnic University Pomona, 3801 West Temple Ave, Pomona, CA 91768, USA
    Vaccine 29:4460-8. 2011
    ..These results suggest that the protective immune response elicited by this vaccine is mediated primarily by a Th2 mechanism...
  8. doi request reprint Amphotericin B lipid preparations: what are the differences?
    J P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Clin Microbiol Infect 14:25-36. 2008
    ..With proven efficacy demonstrated during the past decade, it is expected that amphotericin B lipid formulations will remain an important part of antifungal drug therapy...
  9. pmc Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections
    J A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, California, USA
    Antimicrob Agents Chemother 56:218-30. 2012
    ..flavus infection responded well to L-AmBi but not to caspofungin...
  10. ncbi request reprint Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis
    Jill P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 54:1096-102. 2004
    ..This study was done to determine whether high dose AmBisome (4-20 mg/kg), given intermittently, could reduce the frequency of dosing needed to treat murine systemic candidiasis when compared with conventional daily treatment...
  11. ncbi request reprint Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines
    William A Ernst
    Molecular Express, Inc 13310 S Figueroa Street, Los Angeles, CA 90061, USA
    Vaccine 24:5158-68. 2006
    ....